AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28000167 — intervention group
Group type: COMPARATOR
Intervention: enoxaparin
Number of subjects: 0
Study 26100954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (AcrySof SA60AT)
Number of subjects: 120
Study 26100954 — intervention group
Group type: COMPARATOR
Intervention: Hydrophilic acrylic IOL (BL27)
Number of subjects: 120
Study 23787501 — intervention group
Group type: COMPARATOR
Intervention: Alpha-lipoic acid (600 mg per day for 14 days)
Number of subjects: 50
Study 23787501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (for 2 months)
Number of subjects: 50
Study 23787501 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference group)
Number of subjects: 50
Study 21666557 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure™ hemorrhoidectomy
Number of subjects: 52
Study 21666557 — intervention group
Group type: COMPARATOR
Intervention: Conventional diathermy
Number of subjects: 52
Study 18682969 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol-Dorzolamide drops twice daily (n = 19)
Number of subjects: 38
Study 18682969 — intervention group
Group type: COMPARATOR
Intervention: No eyedrops (control; n = 19)
Number of subjects: 38
Study 17052779 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation 0.4 mg daily
Number of subjects: 61
Study 17052779 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation 1.0 mg daily
Number of subjects: 61
Study 17052779 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation 5.0 mg daily
Number of subjects: 61
Study 17052779 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (FA) supplementation (pooled subjects with baseline NT‐proBNP > 40 ng/L)
Number of subjects: 61
Study 17052779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 15747313 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR
Number of subjects: 11
Study 15747313 — intervention group
Group type: COMPARATOR
Intervention: HDF
Number of subjects: 11
Study 11552016 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE epsilon4 allele carriers (n = 85)
Number of subjects: 374
Study 11552016 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term immunotherapy in epsilon4 carriers
Number of subjects: 374
Study 9722293 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+G‐CSF
Number of subjects: 105
Study 9722293 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 105
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 10
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose meal
Number of subjects: 10
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo meal
Number of subjects: 10
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: First exercise bout
Number of subjects: 10
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Second exercise bout
Number of subjects: 10
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Third exercise bout
Number of subjects: 10
Study 7928875 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy ergometer exercise
Number of subjects: 10
Study 2835976 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 12
Study 2835976 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12
Study 2835976 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 12
Study 2835976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29224843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified preoperative education
Number of subjects: 62
Study 29224843 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preoperative education)
Number of subjects: 62
Study 26919801 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (mean prescribed dose 2.8 mg within the first 24 hours, cumulative dose 6.9 mg over three days)
Number of subjects: 349
Study 26919801 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 349
Study 25689513 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn-containing toothpaste/rinse
Number of subjects: 30
Study 25689513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sr-containing toothpaste/rinse
Number of subjects: 30
Study 25689513 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study 25689513 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn-containing rinse
Number of subjects: 30
Study 25689513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth- and tongue brushing with Sr- and Zn-containing toothpastes
Number of subjects: 30
Study 26527931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 micrograms
Number of subjects: 24
Study 26527931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 110 micrograms
Number of subjects: 24
Study 26527931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 24
Study 26527931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 24
Study 26527931 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) and Fluticasone furoate (FF)
Number of subjects: 24
Study 21434379 — intervention group
Group type: EXPERIMENTAL
Intervention: Geviskon forte (10 ml, 3 times a day)
Number of subjects: 60
Study 21434379 — intervention group
Group type: COMPARATOR
Intervention: Aluminum-magnesium antacid (1 sachet, 3 times a day)
Number of subjects: 60
Study 21434379 — intervention group
Group type: EXPERIMENTAL
Intervention: Geviskon
Number of subjects: 60
Study 18058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligament balancing with an instrumented joint spreader device
Number of subjects: 16
Study 18058086 — intervention group
Group type: COMPARATOR
Intervention: Ligament balancing using fixed thickness spacer blocks
Number of subjects: 16
Study 17162171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 381
Study 17162171 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 381
Study 17162171 — intervention group
Group type: COMPARATOR
Intervention: Reduction with internal fixation
Number of subjects: 381
Study 17162171 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar hemiarthroplasty
Number of subjects: 381
Study 17162171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 381
Study 12914399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (iodide 150 microgram + Levothyroxine 75 microgram)
Number of subjects: 0
Study 12914399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (150 microgram iodide + 75 microgram L-thyroxine)
Number of subjects: 0
Study 12914399 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine monotherapy
Number of subjects: 0
Study 12914399 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide or combination therapy
Number of subjects: 0
Study 12914399 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups with adequate controls and adjustment of Levothyroxine dosage
Number of subjects: 0
Study 12914399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Levothyroxine and iodide
Number of subjects: 0
Study 10707032 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid)
Number of subjects: 168
Study 10707032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 9018517 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (trial G)
Number of subjects: 9
Study 9018517 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose plus branched-chain amino acids (BCAA: trial B)
Number of subjects: 9
Study 9018517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (trial P)
Number of subjects: 9
Study 1527319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (164 micrograms, twice a day for 7 days)
Number of subjects: 12
Study 1527319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4076119 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise group (80% maximum heart rate)
Number of subjects: 33
Study 4076119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group (55% maximum heart rate)
Number of subjects: 33
Study 4076119 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 33
Study 30361960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprout soybean milk (SS)
Number of subjects: 288
Study 30361960 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean milk (S)
Number of subjects: 288
Study 30361960 — intervention group
Group type: COMPARATOR
Intervention: Rice milk (C)
Number of subjects: 288
Study 28870836 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group exercise
Number of subjects: 50
Study 28870836 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical care
Number of subjects: 50
Study 28870836 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based manual therapy and individual exercise
Number of subjects: 50
Study 27504562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioside GM1
Number of subjects: 140
Study 27504562 — intervention group
Group type: COMPARATOR
Intervention: Control group (antiviral, analgesic, and neurotrophic agents)
Number of subjects: 140
Study 25110443 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppository)
Number of subjects: 665
Study 25110443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665
Study 22679142 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 1362
Study 22679142 — intervention group
Group type: COMPARATOR
Intervention: Coumarin treatment
Number of subjects: 1362
Study 20926006 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegic infusion via the aortic root and additional cardioplegia via vein or free arterial grafts (group B)
Number of subjects: 0
Study 20926006 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cardioplegic infusion only via the aortic root (group A)
Number of subjects: 0
Study 18828743 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccination (MV) at 6 and 9 months
Number of subjects: 2200
Study 18828743 — intervention group
Group type: COMPARATOR
Intervention: Measles vaccination (MV) at 9 months only
Number of subjects: 2200
Study 18828743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 2200
Study 16096169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol (E(2))
Number of subjects: 176
Study 16096169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC)
Number of subjects: 176
Study 16096169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 16096169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg estradiol (E(2))/3.75 mg nomegestrol acetate (E(2)/NOMAC) vs 1.5 mg estradiol (E(2))
Number of subjects: 176
Study 12814152 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI (50 microg b.d.)
Number of subjects: 11
Study 12814152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10968237 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (3.3 mg/kg body weight daily)
Number of subjects: 20
Study 8792730 — intervention group
Group type: EXPERIMENTAL
Intervention: Predonation of 2 autologous units of blood before THR
Number of subjects: 80
Study 8792730 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving homologous blood transfusion
Number of subjects: 80
Study 8792730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (predonation and control)
Number of subjects: 80
Study 1637513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 70
Study 1637513 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive treatment
Number of subjects: 70
Study 6383009 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein at a level of 1.5 g/kg desirable weight per day
Number of subjects: 6
Study 6383009 — intervention group
Group type: COMPARATOR
Intervention: Identical diet with half the protein replaced by carbohydrate
Number of subjects: 6
Study 29713890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic collagen sponge with cyanoacrylate
Number of subjects: 44
Study 29713890 — intervention group
Group type: COMPARATOR
Intervention: Hemostatic collagen sponge
Number of subjects: 44
Study 29713890 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft width < 14 mm
Number of subjects: 44
Study 29672821 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day, up-titrated to 80 mg after 6 weeks
Number of subjects: 78
Study 29672821 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg/day, up-titrated to 40 mg after 6 weeks
Number of subjects: 78
Study 29672821 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 78
Study 27109860 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg purified 5‐CGA
Number of subjects: 16
Study 27109860 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg purified 5‐CGA
Number of subjects: 16
Study 27109860 — intervention group
Group type: COMPARATOR
Intervention: 0 mg purified 5‐CGA (control group)
Number of subjects: 16
Study 27109860 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg purified (‐)‐epicatechin (positive control)
Number of subjects: 16
Study 24581245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 262
Study 24581245 — intervention group
Group type: COMPARATOR
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 262
Study 23273022 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed net (LLIN)
Number of subjects: 100
Study 23273022 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT) for uncomplicated malaria
Number of subjects: 100
Study 23273022 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticide-treated bed net (LLIN) and ACT
Number of subjects: 100
Study 20959430 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride (30g infusion)
Number of subjects: 20
Study 20959430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 20
Study 17600452 — intervention group
Group type: EXPERIMENTAL
Intervention: GTH-Only
Number of subjects: 1071
Study 17600452 — intervention group
Group type: EXPERIMENTAL
Intervention: GTH-Plus
Number of subjects: 1071
Study 17600452 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1071
Study 16259308 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser acupuncture (0.5J delivered to six to eight acupuncture sites, twice weekly for four weeks then weekly for a further four weeks)
Number of subjects: 30
Study 16259308 — intervention group
Group type: COMPARATOR
Intervention: Sham control (inactive laser treatment)
Number of subjects: 30
Study 11570619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 20
Study 11570619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9762021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% calcipotriol ointment twice daily
Number of subjects: 0
Study 9762021 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus ointment once daily
Number of subjects: 0
Study 9762021 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment once daily
Number of subjects: 0
Study 7801756 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament injury group (n=20)
Number of subjects: 46
Study 7801756 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=26)
Number of subjects: 46
Study 7801756 — intervention group
Group type: EXPERIMENTAL
Intervention: Notch width ≤ 17 mm
Number of subjects: 46
Study 3432357 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TRP) 2 g
Number of subjects: 39
Study 3432357 — intervention group
Group type: COMPARATOR
Intervention: Very low dose of L-tryptophan (0.04 g)
Number of subjects: 39
Study 30541645 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal replacement therapy (RRT)
Number of subjects: 132
Study 30541645 — intervention group
Group type: COMPARATOR
Intervention: Non-RRT
Number of subjects: 132
Study 30541645 — intervention group
Group type: EXPERIMENTAL
Intervention: Early RRT (initial RRT on KDIGO stage‐2)
Number of subjects: 132
Study 30541645 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed RRT (including self-improvement without RRT on KDIGO stage‐2 and initial RRT on KDIGO stage‐3)
Number of subjects: 132
Study 28199143 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 246
Study 28199143 — intervention group
Group type: COMPARATOR
Intervention: R-HDS
Number of subjects: 246
Study 23439365 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 50 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81
Study 23439365 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 50 mg twice daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81
Study 23439365 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 100 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81
Study 23439365 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 150 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81
Study 23439365 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 100 mg twice daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81
Study 23439365 — intervention group
Group type: EXPERIMENTAL
Intervention: IDX184 200 mg once daily + pegylated interferon-α2a and ribavirin
Number of subjects: 81
Study 23439365 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon-α2a and ribavirin alone
Number of subjects: 81
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25% glucose and 18.75% dextrin
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25% sucrose and 18.75% dextrin
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25% maltose and 18.75% dextrin
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% dextrin
Number of subjects: 0
Study 22080004 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mL diluent-injected control
Number of subjects: 0
Study 22080004 — intervention group
Group type: COMPARATOR
Intervention: Noninjected control
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: All carbohydrate treatments except glucose and dextrin combination
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: All carbohydrates except for 25% dextrin treatment
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: E19 to the day of hatch
Number of subjects: 0
Study 22080004 — intervention group
Group type: EXPERIMENTAL
Intervention: Day of hatch
Number of subjects: 0
Study 17662284 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser thinning of the zona pellucida (ZP) using a 1,480-nm noncontact laser
Number of subjects: 180
Study 17662284 — intervention group
Group type: COMPARATOR
Intervention: Laser breaching of the zona pellucida (ZP) creating a hole about 30 microm in size
Number of subjects: 180
Study 17228991 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (decaffeinated coffee)
Number of subjects: 90
Study 17228991 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated orange juice (true information)
Number of subjects: 90
Study 17228991 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (both treatments)
Number of subjects: 90
Study 17228991 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (correctly informed participants)
Number of subjects: 90
Study 17228991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no caffeine or placebo)
Number of subjects: 90
Study 12577196 — intervention group
Group type: EXPERIMENTAL
Intervention: Local DEXA analysis
Number of subjects: 80
Study 12577196 — intervention group
Group type: COMPARATOR
Intervention: Central DEXA analysis
Number of subjects: 80
Study 10666539 — intervention group
Group type: EXPERIMENTAL
Intervention: granisetron+5-HT
Number of subjects: 24
Study 10666539 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol+5-HT
Number of subjects: 24
Study 10666539 — intervention group
Group type: COMPARATOR
Intervention: 5-HT
Number of subjects: 24
Study 10666539 — intervention group
Group type: COMPARATOR
Intervention: saline+5-HT
Number of subjects: 24
Study 9004051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day)
Number of subjects: 24
Study 9004051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-80 mg/day)
Number of subjects: 24
Study 8403960 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (10 mg/mL)
Number of subjects: 30
Study 8403960 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (5 mg/mL)
Number of subjects: 30
Study 8403960 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.5 mg/mL)
Number of subjects: 30
Study 6406471 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 6406471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31520611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS during surgical skill training
Number of subjects: 22
Study 31520611 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS during surgical skill training
Number of subjects: 22
Study 31520611 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS paired with surgical training
Number of subjects: 22
Study 31520611 — intervention group
Group type: COMPARATOR
Intervention: Surgical training without tDCS
Number of subjects: 22
Study 29618772 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorous application
Number of subjects: 0
Study 29618772 — intervention group
Group type: COMPARATOR
Intervention: Drought stress
Number of subjects: 0